Despite decades of research, diagnostic tests with specificity and accuracy for early breast cancer are yet unavailable. Major problems associated with poor diagnosis are either due to incompetency of reported biomarkers or small volume of patients under study. Moreover, heterogeneity of the disease further complicates the struggle of identifying effective biomarkers. Therefore, to improve the survival rate, look for new, sensitive and specific biomarkers for early breast cancer diagnosis is need of hour. In this study, we have reviewed recently reported serum biomarkers and categorized them based on their biomolecular nature such as protein, ctDNA, epigenetics regulation and miRNA. Potential role of these available biomarkers in early diagnosis of breast cancer has also been discussed. Based on the facts obtained from literature review, it is revealed that using any individual biomolecule as a biomarker is not sufficient to diagnose breast cancer at early stages rather it is suggested that a panel of proteins or miRNAs would offer better sensitivity and specificity. Whereas, unavailability of a potential ctDNA and epigenetics regulation candidate for diagnostic purpose is and suggest the use of more sophisticated techniques to unwound these regulations in serum especially at early stages of breast cancer.
Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3